Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas.
BACKGROUND
The production of the cytokine interferon gamma (IFN gamma) by activated peripheral blood mononuclear cells may be reduced in patients with invasive cervical carcinoma. This study was designed to assess the prognostic value of intratumoral IFN gamma messenger RNA (mRNA) levels in such patients.


METHODS
Biopsy specimens of primary cervical lesions were obtained from 27 patients with invasive squamous cell carcinoma before they received any therapy. Two prognostic groups were considered: 1) a group of 14 patients who had no apparent disease recurrence and who were alive 2 years after diagnosis (good-prognosis group) and 2) a group of 13 patients who had disease recurrence or died during the 2-year follow-up (poor-prognosis group). A competitive reverse transcription-polymerase chain reaction assay was used to measure levels of IFN gamma and beta actin mRNA. The expression of human leukocyte antigen (HLA) class II proteins (which is stimulated by IFN gamma) in tumor cells was studied by immunostaining.


RESULTS
Tumor specimens from all 14 patients in the good-prognosis group contained more than 10(3) IFN gamma mRNA copies per 5 x 10(5) beta actin mRNA copies, whereas tumor specimens from only six of the 13 patients in the poor-prognosis group contained this level of IFN gamma mRNA (two-sided P = .006). No clear relationship was observed between levels of IFN gamma mRNA and T-cell or natural killer cell infiltration in tumors; however, a statistically significant association was observed between HLA class II expression on tumor cells and IFN gamma mRNA levels (two-sided P = .01).


CONCLUSIONS
A subgroup of poor-prognosis cervical carcinoma patients who have low levels of intratumoral IFN gamma mRNA was identified.
Tartour
E
E
Laboratoire d'Immunologie Clinique, INSERM U255, Institut Curie, Paris, France. etartour@curie.fr
Gey
A
A
Sastre-Garau
X
X
Lombard Surin
I
I
Mosseri
V
V
Fridman
W H
WH
D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D015342:DNA Probes; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D009361:Neoplasm Invasiveness; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000276:immunology* / Q000473:pathology
D015342:DNA Probes; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D007371:Interferon-gamma